Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Crizotinib). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Crizocent 250 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended Dose: 250 mg orally, twice daily Geriatric Use: No differences in safety or efficacy were observed between older and younger patients. Clinical studies of Crizotinib in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patientsPediatric Dose: The safety and effectiveness of Crizotinib in pediatric patients have not been established.Renal impairment: 250 mg orally, once daily in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis. No starting dose adjustment is needed for patients with mild (ClCr 60-89 mL/min) or moderate (ClCr 30-59 mL/min) renal impairment based on a population pharmacokinetic analysis.Hepatic Impairment: Caution should be used in patients with hepatic impairment
Side Effects
The most common adverse reactions (≥25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.
Cautions & Contraindications
Warnings & Precautions
Hepatotoxicity: Patients should undergo periodic liver testing. Crizocent should be temporarily suspended, dose reduced or permanently suspendedInterstitial lung disease (ILD)/ Pneumonitis: Drug should be permanently discontinued in patients with ILD/ PneumonitisQT interval prolongation: Electrocardiograms and electrolytes in patients who have a history of or predisposition for QTc prolongation, or who are taking medications that prolong QT should be monitored. Crizocent should be temporarily suspended, dose reduced or permanently suspendedBradycardia: Crizocent can cause bradycardia. Heart rate and blood pressure should be regularly monitored. Crizocent should be temporarily suspended, dose reduced or permanently suspendedSevere visual loss: Ophthalmological evaluation should be performed. Crizocent should be discontinued in severe visual lossEmbryo-fetal toxicity: Crizocent can cause fetal harm. Females of reproductive potential should be advised of the potential risk to a fetus and use of effective contraception